USA Dominates Global Actinic Keratosis Market, States DelveInsight in Its New Research Report Available at MarketPublishers.com

17 Jul 2017 • by Natalie Aster

LONDON – The USA takes the lead in terms of prevalence of actinic keratosis (AK) as compared to EU5 and Japan. There were 76,603,272 prevalent cases in the USA as of 2015; and the number is forecast to grow through to 2025.

Amid the topical field therapies for AK one can name ingenol mebutate (ingenol-3-angelate), diclofenac 3%, imiquimod cream 5%, 5% 5-fluorouracil (FU) cream, imiquimod 3.75% and fluorouracil/salicylic acid combination. Patients’ adherence to topical treatment is typically low – close to 50%-55%. High rates of non-adherence to the medical regimen has been witnessed amid the patients choosing topical therapy due to the long duration of therapy. The procedural therapy remains the standard-of-care. 

The USA accounts for the lion’s share of the total AK market as against EU5 nations and Japan. The country’s market size of AK (topical therapies only) was valued at USD 102.62 million as of 2015 and is projected to see a robust CAGR to 2025.

New research study “Actinic Keratosis- Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025” elaborated by DelveInsight offers true, detailed insights into the market on a global level.

The report gives an all-round overview of the disease and worldwide market trends of the disease for the 7 leading markets such as the USA, Italy, Germany, France, Spain, and the UK, and Japan. The research study provides therapeutics market revenue, treatment algorithms and projected AK market size to 2025 across the top 7 markets. The market size is based only on the topical therapies approved for AK. The report also offers global AK epidemiology forecasts through 2025. It identifies the market drivers and restraints, and limelights key unmet medical needs. The research examines the competitive scenario covering both pipeline and marketed portfolio of the indication. AK pipeline provides information on the therapeutics in development and a comparative analysis at different stages. It also offers an all-round analysis on the phase III profile shedding light on clinical research studies, latest developments and a SWOT analysis.

More new research reports by this publisher are available at the DelveInsight page

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com